Published in Am J Respir Crit Care Med on August 01, 1999
Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax (2004) 2.13
Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med (2006) 2.08
Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract (2007) 1.64
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev (2010) 1.52
Asthma exacerbations . 1: epidemiology. Thorax (2006) 1.48
Outcome measures in asthma. Thorax (2000) 1.48
Lower airway rhinovirus burden and the seasonal risk of asthma exacerbation. Am J Respir Crit Care Med (2011) 1.48
Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children. J Allergy Clin Immunol (2008) 1.28
Asthma exacerbations . 4: Prevention. Thorax (2006) 1.17
Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev (2010) 1.16
Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev (2009) 1.14
Retracted Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all? Naunyn Schmiedebergs Arch Pharmacol (2008) 1.12
Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. Chest (2011) 1.10
Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control. BMJ (2007) 1.09
Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax (2013) 1.08
Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations. Lung India (2015) 1.07
Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. BMC Pulm Med (2010) 0.99
Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev (2012) 0.98
The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis. NPJ Prim Care Respir Med (2015) 0.95
Impact of race on the severity of acute episodes of asthma and adrenergic responsiveness. Am J Respir Crit Care Med (2006) 0.93
Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev (2009) 0.92
Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease. Respir Res (2012) 0.86
Effect of a web-based chronic disease management system on asthma control and health-related quality of life: study protocol for a randomized controlled trial. Trials (2011) 0.86
Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir Res (2004) 0.86
Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database Syst Rev (2009) 0.85
Asthma attacks: how can we reduce the risks? NPJ Prim Care Respir Med (2015) 0.84
Treatment compliance, passive smoking, and asthma control: a three year cohort study. Arch Dis Child (2003) 0.83
Low dose inhaled corticosteroids and the prevention of death from asthma. Thorax (2001) 0.82
Inflammatory and Co-Morbid Features of Patients with Severe Asthma and Frequent Exacerbations. Am J Respir Crit Care Med (2016) 0.80
Management of asthma in the elderly patient. Clin Interv Aging (2013) 0.80
Inhaled Corticosteroids. Pharmaceuticals (Basel) (2010) 0.79
Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease. Thorax (2000) 0.78
Measurements of fractional exhaled nitric oxide in pediatric asthma. Korean J Pediatr (2013) 0.78
Rates and predictors of uncontrolled bronchial asthma in elderly patients from western Romania. Clin Interv Aging (2015) 0.77
New therapies and management strategies in the treatment of asthma: patient-focused developments. J Asthma Allergy (2010) 0.76
Modeling the impact of increased adherence to asthma therapy. PLoS One (2012) 0.76
The Effectiveness of Web-Based Asthma Self-Management System, My Asthma Portal (MAP): A Pilot Randomized Controlled Trial. J Med Internet Res (2016) 0.76
Asthma worsenings: approaches to prevention and management from the Asthma Worsenings Working Group. Can Respir J (2009) 0.75
Revisiting early intervention in adult asthma. ERJ Open Res (2015) 0.75
Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations. J Aerosol Med Pulm Drug Deliv (2016) 0.75
The role of inflammation resolution speed in airway smooth muscle mass accumulation in asthma: insight from a theoretical model. PLoS One (2014) 0.75
Section 3. A discussion of flexible dosing and patient-centered therapy: highlights of the asthma summit 2009: beyond the guidelines. World Allergy Organ J (2010) 0.75
Asthma exacerbations: prevention is better than cure. Ther Clin Risk Manag (2005) 0.75
Detection and home management of worsening asthma symptoms. Ann Allergy Asthma Immunol (2009) 0.75
Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08
Development and validation of a questionnaire to measure asthma control. Eur Respir J (1999) 9.35
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med (1997) 8.48
Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J (1995) 7.03
Lymphosarcoma of the Small and Large Intestines. Ann Surg (1932) 6.39
Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J (2003) 6.23
Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med (1996) 5.53
Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med (2001) 5.47
Increased nitric oxide in exhaled air of asthmatic patients. Lancet (1994) 5.39
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 5.25
Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J (2005) 5.24
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med (1999) 4.65
Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) (1998) 4.31
Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma. Thorax (1999) 4.11
Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. J Allergy Clin Immunol (1981) 4.03
Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J Exp Med (2001) 3.90
Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest (2000) 3.84
Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl (1993) 3.82
Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J (2005) 3.66
Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet (2001) 3.48
Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med (1999) 3.44
Air pollution and development of asthma, allergy and infections in a birth cohort. Eur Respir J (2007) 3.42
Distribution of the intermediate elements operating in ER to Golgi transport. J Cell Sci (1991) 3.34
Asthma as an axon reflex. Lancet (1986) 3.26
Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A (1998) 3.24
Single-dose slow-release aminophylline at night prevents nocturnal asthma. Lancet (1982) 3.21
A new perspective on concepts of asthma severity and control. Eur Respir J (2008) 3.16
Exhaled markers of pulmonary disease. Am J Respir Crit Care Med (2001) 3.14
A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med (1992) 3.13
Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol (2000) 3.13
Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy (1994) 3.04
Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax (1999) 3.00
Neural control of human airways in health and disease. Am Rev Respir Dis (1986) 2.97
Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. N Engl J Med (2016) 2.89
Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax (2004) 2.85
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature (2001) 2.83
Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med (1990) 2.80
Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J (1997) 2.79
Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med (1997) 2.77
Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax (1998) 2.71
Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax (2005) 2.69
Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet (2001) 2.68
Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest (2000) 2.67
Exacerbations of chronic obstructive pulmonary disease. Eur Respir J (2007) 2.65
Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis (1987) 2.64
Cytokines in asthma. Thorax (1999) 2.64
Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med (1999) 2.53
Luminescent metal-organic frameworks. Chem Soc Rev (2009) 2.46
Asthma at 8 years of age in children born by caesarean section. Thorax (2008) 2.45
Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet (1986) 2.41
PC(20) adenosine 5'-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med (2001) 2.36
Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med (2000) 2.33
Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med (1992) 2.32
Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med (1996) 2.32
Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice. J Immunol (1998) 2.32
Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis (1986) 2.29
Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med (1995) 2.28
Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J (2008) 2.23
Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis (1990) 2.23
Circulating catecholamines in exercise and hyperventilation induced asthma. Thorax (1981) 2.22
The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect (1993) 2.20
Exhaled carbon monoxide in childhood asthma. J Pediatr (1999) 2.19
Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med (1998) 2.19
Elevated fusiform cell activity in the dorsal cochlear nucleus of chinchillas with psychophysical evidence of tinnitus. J Neurosci (2002) 2.19
Severe exacerbations predict excess lung function decline in asthma. Eur Respir J (2007) 2.18
Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J (2001) 2.18
Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J (2004) 2.18
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Tumor necrosis factor causes bronchial hyperresponsiveness in rats. Am Rev Respir Dis (1992) 2.11
Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med (2001) 2.08
Beta-agonists--friends or foes? Eur Respir J (1991) 2.06
Inhaled corticosteroids in COPD: a case in favour. Eur Respir J (2009) 2.06
STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J (2004) 2.06
Late asthmatic responses. Am Rev Respir Dis (1987) 2.05
The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J (2004) 2.05
Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax (1997) 2.04
Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J (2002) 2.04
Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med (2000) 2.03
Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax (2000) 2.02
Association of a promoter polymorphism of the CD14 gene and atopy. Am J Respir Crit Care Med (2001) 1.99
The effect of airway epithelium on smooth muscle contractility in bovine trachea. Br J Pharmacol (1985) 1.98
Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Thorax (1992) 1.98
Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun (2004) 1.98
Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J (2010) 1.97
Expression of inducible nitric oxide in human lung epithelial cells. Biochem Biophys Res Commun (1994) 1.96
Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 1.94
Effects of long-term treatment with corticosteroids in COPD. Chest (1996) 1.94